[吉非替尼诱发的穿通性皮肤病]

[Gefitinib-induced perforating dermatosis].

作者信息

Fernández-Guarino Montse, Aldanondo Isabel, González-García Carmen, Garrido Pilar, Marquet Ainhoa, Pérez-García Bibiana, Jaén Pedro

机构信息

Servicio de Dermatología, Hospital Ramón y Cajal, Madrid, España.

出版信息

Actas Dermosifiliogr. 2006 Apr;97(3):208-11. doi: 10.1016/s0001-7310(06)73383-x.

DOI:10.1016/s0001-7310(06)73383-x

PMID:16796971

Abstract

Gefitinib (Iressa) is a new antineoplastic agent that acts by selectively inhibiting epidermal growth factor receptor tyrosine kinase (EGFR-TK). It has shown activity against several solid tumors. Because of their action mechanism, gefitinib and other tyrosine kinase inhibitors have been associated with multiple cutaneous effects, most of which are mild and well tolerated. We present a case of perforating dermatosis after treatment with gefitinib.

摘要

吉非替尼（易瑞沙）是一种新型抗肿瘤药物，其作用机制是选择性抑制表皮生长因子受体酪氨酸激酶（EGFR-TK）。它已显示出对多种实体瘤有活性。由于其作用机制，吉非替尼和其他酪氨酸激酶抑制剂与多种皮肤效应有关，其中大多数是轻微的且耐受性良好。我们报告一例吉非替尼治疗后发生的穿通性皮肤病病例。